The former Theranos lab director testified on Tuesday. He left the company for one simple reason: The blood test technology didn’t work.
Adam Rosendorff, a key government witness, took his fifth day in a criminal fraud trial by former CEO Elizabeth Holmes.
“There was tremendous pressure on the company to show that the technology was successful,” Rosendorff said during a cross-examination. “It came from above and permeated through research and development.”
He testified to Theranos executives, including Holmes, about their struggle to address concerns about wrongful issues within the lab.
Of Holmes, Rosendorff said, “She wanted to rapidly expand the use of Edison from the time of rollout to the rest of the time I was in the office.” Edison was one of the company’s blood test analyzers.
Rosendorff testified that he left the company in November 2014, feeling “very suspicious” with Edison and company.
“I realized that the problem of doctoral integrity was not to stay there, but to amplify results I didn’t believe in,” Rosendorff said. “I’ve learned that management isn’t honest about diverting resources to solve problems.”
Holmes faces 12 criminal fraud charges in connection with misleading patients and doctors by charging investors millions of dollars. He pleaded not guilty and denied any misconduct. Holmes, who was once a Silicon Valley miracle, claimed that startup Theranos could run hundreds of tests with just the stab of a finger.
Rosendorff, who left Theranos seven years ago, said trial preparation and testimony turned his life upside down.
“The stress of meeting the government, traveling from San Diego to San Francisco to the SEC to meet with the government,” Rosendorff said. “In short, this is the issue we have in mind. We at Theranos need to have a very unpleasant experience and a lot of media attention.”
The redirect followed a fierce and lengthy four-day cross-examination by Holmes’ defense attorney, Lance Wade, who repeatedly tried to undermine Rosendorff’s previous testimony.
In an effort to challenge his integrity, Wade pointed out that there were some discrepancies in Rosendorff’s deposit in one case in addition to his testimony on the stand. Wade also asked about sensitive emails that Theranos sent to his personal Gmail account when Rosendorff left.
“Maybe two pages of detailed health information for 100 patients,” Wade said. “It’s a HIPAA violation, isn’t it?”
“I don’t know,” answered Rosendorff.
Earlier, Rosendorff testified that he forwarded company emails to himself in connection with a federal investigation and because he was considering filing a whistleblower case.
“You were sending it, so you can try to make money in the proceedings,” Wade said.
“It’s completely different,” answered Rosendorff.
“We also stole confidential corporate information,” Wade said.
“I don’t remember,” said Rosendorff.
Rosendorff’s testimony will end on Wednesday.